EGFR and NF-kB: partners in cancer

[en] Oncogenic proteins cooperate to promote tumor development and progression by sustaining cell proliferation, survival and invasiveness. Constitutive EGFR and NF-kappaB activities are seen in multiple solid tumors and combine to provide oncogenic signals to cancer cells. Understanding how these oncogenic pathways are connected is critical, given their role in intrinsic or acquired resistance to targeted anti-cancer therapies. We review molecular mechanisms by which both EGFR- and NF-kappaB-dependent pathways establish positive loops to increase their oncogenic potential. We also describe how NF-kappaB promotes resistance to EGFR inhibitors.

Research center :

Giga-Signal Transduction - ULiège

Disciplines :

Oncology

Author, co-author :

Shostak, Kateryna ; Université de Liège > Département de pharmacie > Chimie médicale

Chariot, Alain ; Université de Liège > Département de pharmacie > Chimie médicale

Language :

English

Title :

EGFR and NF-kB: partners in cancer

Publication date :

June 2015

Journal title :

Trends in Molecular Medicine

ISSN :

1471-4914

Publisher :

Elsevier Science, Oxford, United Kingdom

Volume :

Pages :

385-393

Peer reviewed :

Peer Reviewed verified by ORBi

Funders :

WELBIO - Institut wallon virtuel de recherche d'excellence dans les domaines des sciences de la vie [BE]
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
Télévie [BE]

Available on ORBi :

since 06 June 2015

Statistics

Number of views

914 (8 by ULiège)

Number of downloads

1701 (7 by ULiège)

More statistics

Scopus citations^®

172

Scopus citations^®
without self-citations

172

OpenCitations

149

Bibliography

Sordella R., et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
Shoelson S.E. SH2 and PTB domain interactions in tyrosine kinase signal transduction. Curr. Opin. Chem. Biol. 1997, 1:227-234.
Morandell S., et al. Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network. Proteomics 2008, 8:4383-4401.
Lowenstein E.J., et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 1992, 70:431-442.
Okutani T., et al. Grb2/Ash binds directly to tyrosines 1068 and 1086 and indirectly to tyrosine 1148 of activated human epidermal growth factor receptors in intact cells. J. Biol. Chem. 1994, 269:31310-31314.
Sakaguchi K., et al. Shc phosphotyrosine-binding domain dominantly interacts with epidermal growth factor receptors and mediates Ras activation in intact cells. Mol. Endocrinol. 1998, 12:536-543.
Olayioye M.A., et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19:3159-3167.
Wykosky J., et al. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chin. J. Cancer 2011, 30:5-12.
Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 2009, 9:463-475.
Kris M.G., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
Lynch T.J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
Paez J.G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
Ekstrand A.J., et al. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 1991, 51:2164-2172.
Wong A.J., et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:2965-2969.
Sharma S.V., et al. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007, 7:169-181.
Cheng L., et al. Molecular pathology of lung cancer: key to personalized medicine. Mod. Pathol. 2012, 25:347-369.
Kobayashi S., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
Yu H.A., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 2013, 19:2240-2247.
Imai K., Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 2006, 6:714-727.
Zhou W., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.
Quesnelle K.M., Grandis J.R. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin. Cancer Res. 2011, 17:5935-5944.
Engelman J.A., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
Sergina N.V., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441.
Wheeler D.L., et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008, 27:3944-3956.
Pinkas-Kramarski R., et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 1996, 15:2452-2467.
Campbell M.R., et al. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin. Cancer Res. 2010, 16:1373-1383.
Ma J., et al. Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol. Cancer 2014, 13:105.
Ghosh S., Hayden M.S. New regulators of NF-kappaB in inflammation. Nat. Rev. Immunol. 2008, 8:837-848.
Biswas D.K., et al. Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8542-8547.
Sun L., Carpenter G. Epidermal growth factor activation of NF-kappaB is mediated through IkappaBalpha degradation and intracellular free calcium. Oncogene 1998, 16:2095-2102.
Biswas D.K., et al. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:10137-10142.
Le Page C., et al. EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate 2005, 65:130-140.
Yang W., et al. EGFR-induced and PKCepsilon monoubiquitylation-dependent NF-kappaB activation upregulates PKM2 expression and promotes tumorigenesis. Mol. Cell 2012, 48:771-784.
Jiang T., et al. CARMA3 is crucial for EGFR-Induced activation of NF-kappaB and tumor progression. Cancer Res. 2011, 71:2183-2192.
McAllister-Lucas L.M., et al. CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:139-144.
Mahanivong C., et al. Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene 2008, 27:1273-1280.
Thome M. Multifunctional roles for MALT1 in T-cell activation. Nat. Rev. Immunol. 2008, 8:495-500.
De S., et al. EGF receptor uses SOS1 to drive constitutive activation of NFkappaB in cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:11721-11726.
Zhao C., et al. Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos. Nat. Cell Biol. 2007, 9:706-712.
Shostak K., et al. NF-kappaB-induced KIAA1199 promotes survival through EGFR signalling. Nat. Commun. 2014, 5:5232.
Kuscu C., et al. Transcriptional and epigenetic regulation of KIAA1199 gene expression in human breast cancer. PLoS ONE 2012, 7:e44661.
Nottingham L.K., et al. Aberrant IKKalpha and IKKbeta cooperatively activate NF-kappaB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer. Oncogene 2014, 33:1135-1147.
Ramnarain D.B., et al. RIP1 links inflammatory and growth factor signaling pathways by regulating expression of the EGFR. Cell Death Differ. 2008, 15:344-353.
Bentires-Alj M., et al. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003, 22:90-97.
Guo C., Stark G.R. FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-kappaB. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:7968-7973.
Kim L., Wong T.W. Growth factor-dependent phosphorylation of the actin-binding protein cortactin is mediated by the cytoplasmic tyrosine kinase FER. J. Biol. Chem. 1998, 273:23542-23548.
Kim L., Wong T.W. The cytoplasmic tyrosine kinase FER is associated with the catenin-like substrate pp120 and is activated by growth factors. Mol. Cell. Biol. 1995, 15:4553-4561.
Bivona T.G., et al. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011, 471:523-526.
Dermawan J.K., et al. Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-kappaB, and cell-cycle progression in non-small cell lung cancer. Mol. Cancer Ther. 2014, 13:2203-2214.
Dean M., et al. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
Seguin L., et al. An integrin beta(3)-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat. Cell Biol. 2014, 16:457-468.
Guertin D.A., Sabatini D.M. The pharmacology of mTOR inhibition. Sci. Signal. 2009, 2:pe24.
Tanaka K., et al. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov. 2011, 1:524-538.
Puliyappadamba V.T., et al. Opposing effect of EGFRWT on EGFRvIII-mediated NF-kappaB activation with RIP1 as a cell death switch. Cell Rep. 2013, 4:764-775.
Kusne Y., et al. Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFalpha in glioblastoma. Sci. Signal. 2014, 7:ra75.
Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin. Cancer Res. 2007, 13:1076-1082.
Vermorken J.B., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 2007, 25:2171-2177.
Wheeler S.E., et al. Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene 2010, 29:5135-5145.
Wheeler S.E., et al. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. Clin. Cancer Res. 2012, 18:2850-2860.
Pernas F.G., et al. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clin. Cancer Res. 2009, 15:2361-2372.
Adams J., Kauffman M. Development of the proteasome inhibitor Velcade (bortezomib). Cancer Invest. 2004, 22:304-311.
Allen C., et al. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. Clin. Cancer Res. 2008, 14:4175-4185.
Allen C.T., et al. CCR 20th Anniversary Commentary: preclinical study of proteasome inhibitor bortezomib in head and neck cancer. Clin. Cancer Res. 2015, 21:942-943.
Argiris A., et al. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clin. Cancer Res. 2011, 17:5755-5764.
Sloss C.M., et al. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin. Cancer Res. 2008, 14:5116-5123.
Skaar J.R., et al. SCF ubiquitin ligase-targeted therapies. Nat. Rev. Drug Discov. 2014, 13:889-903.
Kobori M., et al. Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ. 2004, 11:123-130.
Hertlein E., et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood 2010, 116:45-53.
Hu J.C., et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J. Am. Acad. Dermatol. 2007, 56:317-326.
Lacouture M.E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat. Rev. Cancer 2006, 6:803-812.
Mascia F., et al. Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. Sci. Transl. Med. 2013, 5:199ra110.
Lichtenberger B.M., et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci. Transl. Med. 2013, 5:199ra111.
Lee D.F., Hung M.C. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin. Cancer Res. 2008, 14:5656-5662.
Karin M., et al. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov. 2004, 3:17-26.
Verstrepen L., Beyaert R. Receptor proximal kinases in NF-kappaB signaling as potential therapeutic targets in cancer and inflammation. Biochem. Pharmacol. 2014, 92:519-529.
Popovic D., et al. Ubiquitination in disease pathogenesis and treatment. Nat. Med. 2014, 20:1242-1253.
Hynes N.E., MacDonald G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 2009, 21:177-184.
Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol. Res. 2014, 79:34-74.
Hayden M.S., Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012, 26:203-234.
Chen J., Chen Z.J. Regulation of NF-kappaB by ubiquitination. Curr. Opin. Immunol. 2013, 25:4-12.